Xinjiang Cicon Habo Uygur Medicine Co, Ltd was established in December 2000 by Xinjiang Cicon Pharmaceutical Factory (founded in 1995) and the Xinjiang Uygur Medicine Research Institute. The Xinjiang Production and Construction Corps Pharmaceutical Company added 12.6 million yuan in June 2003 to restructure it into a limited-liability company in the Urumqi high-tech industrial zone, with 30 million yuan of registered capital.

The company, located at No 22 Yingbin Road of Urumqi city, occupies a land of 40,000 square meters. The joint-equity company is invested in by the Xinjiang Production and Construction Corps Pharmaceutical Company, Urumqi Railway Bureau diversified economy development center, Habo Co, Ltd and senior executives of the companies.

So far, it has developed 17 types of medicine that have been approved by the State Food and Drug Administration, and two national protected traditional Chinese medicines. It is developing seven new medicine products. It has applied for patent protection for seven drugs. In the past two years, the company has realized 30 million yuan in sales revenues and four million yuan in profits and taxes with the small production capacity in the existing 600m² preparation workshop.

The company has finished GMP technological reform and passed GMP attestation. It has constructed a comprehensive preparation workshop, extraction workshop, and sewage treatment station. When the new facilities are completed, the company will be able to annually produce 1.2 million boxes of oral liquids, 300 million tablets, 50 million capsules, one million boxes of syrups, two million bottles of solutions, 150 tons of granules, and 30 million granules of suppositories. They will be worth 200 million yuan in output values in a year to make the company the largest and most advanced high-tech business in developing, producing and selling Uygur medicines. In 2004, the company had 55.85 million yuan in total assets, 36.18 million yuan net assets, 13.72 million yuan in sales revenues, 400,000 yuan profits, and 1.22 million yuan in taxes.

The company has 60 technical personnel, including three people with professor-equivalent technical titles, four people with associate professional equivalent technical titles, three people with PhD degrees and seven people with master’s degree. Ethnic minorities account for 35 percent of the staff workers. The company has quality technical and talent support in Uygur medicine research. Dr. Hamulati, an expert enjoying special allowances from the State Council, a member of the national new drug jury committee, and a member of the national traditional Chinese medicine protection review committee, acts as the chief scientist of the company research center. The technology research center of the company works under the guidance of famous pharmaceutical experts, with five from foreign countries, five from other provinces, and two from Xinjiang. They develop projects in pharmacology, toxicology, preclinical medicine, and pharmacy fields along with the Uygur medicine research institute. The lab has met the third-grade requirements stipulated by the State Administration of Traditional Chinese Medicine.

The company is mainly engaged in producing Xipayimaizibizi oral liquid and Xipayi gum solid liquid, for treating prostatitis and periodontosis respectively.

The products have been promoted as key modern Uygur medicines by the State Administration of Traditional Chinese Medicine in nationwide markets. Xipayi gum solid liquid has been listed as a national OTC class-A medicine under the health-care project. It has won third-class prize for scientific progress of national traditional Chinese medicines. The company has won fund support for four research and industrialization projects from the National Planning Commission, State Economic and Trade Commission, and the Ministry of Science and Technology for small and medium-sized enterprise technological innovation. It also gained funds from the National Torch Program Office. In 2001, the company was approved by the State Ethic Affairs Commission to supply special procurement products for ethnic minorities. It has been appraised by the regional and municipal governments among the top 30 emerging enterprises and a “Little Giant” enterprise in the city.

In addition to the research and development (R&D) and talent advantages, the company has sharpened system innovation. It is a consortium of Xinjiang Production and Construction Corps, and railway bureau and local companies. The Xinjiang Production and Construction Corps Pharmaceutical Company gave large investments to add vitality to the company and to complement each other’s advantages with crude drug plantation. The corporation has widespread drugstore outlets in the region. Urumqi alone has 100 drugstore chained outlets named under Xinjiang Production and Construction Corps.

The company has also set up alliances with Tsinghua UNIS to establish a nationwide sales network in the OTC market. They have set up two Uygur medical treatment centers in foreign countries and founded exclusive agencies in Arab nations, to push Uygur medicines into the global market.

The company is striving to develop into a flagship in Chinese modern Uygur medicine production, in a bid to benefit people across the world.